KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells

[1]  Min Zhang,et al.  miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells , 2016, OncoTargets and therapy.

[2]  G. Lou,et al.  MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression , 2016, Tumor Biology.

[3]  Yang Li,et al.  High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis , 2015, Oncotarget.

[4]  A. Difeo,et al.  Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance , 2015, Oncotarget.

[5]  G. Lou,et al.  miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6 , 2015, Molecular Cancer.

[6]  Yun Xiao,et al.  miR-429 inhibits migration and invasion of breast cancer cells in vitro , 2014, International journal of oncology.

[7]  Yingnan Sun,et al.  miR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma , 2014, Molecular and Cellular Biochemistry.

[8]  Moonsup Lee,et al.  PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation. , 2013, Molecular cell.

[9]  H. Zhang,et al.  Expression of KIAA0101 protein is associated with poor survival of esophageal cancer patients and resistance to cisplatin treatment in vitro , 2013, Laboratory Investigation.

[10]  Leitai Shi,et al.  Elevated KIAA0101 expression is a marker of recurrence in human gastric cancer , 2013, Cancer science.

[11]  Wei Li,et al.  MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2. , 2013, Cancer letters.

[12]  Zhenpeng Qiu,et al.  Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin‐induced apoptosis by inhibiting p53 activation , 2012, Hepatology.

[13]  A. Al-Niaimi,et al.  Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.

[14]  E. Kebebew,et al.  KIAA0101 Is Overexpressed, and Promotes Growth and Invasion in Adrenal Cancer , 2011, PloS one.

[15]  Christopher G. Hill,et al.  Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. , 2011, Gynecologic oncology.

[16]  M. Hung,et al.  Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth , 2011, Molecular Cancer Therapeutics.

[17]  E. Lengyel.  Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[18]  D. Matei,et al.  Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. , 2010, Gynecologic oncology.

[19]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[20]  Zhihui Feng,et al.  A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. , 2009, Gynecologic oncology.

[21]  G. Packham,et al.  MicroRNAs: key players in carcinogenesis and novel therapeutic targets. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  R. Gregory,et al.  Many roads to maturity: microRNA biogenesis pathways and their regulation , 2009, Nature Cell Biology.

[23]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[24]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[25]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[26]  B. Monk,et al.  Wnt signaling in ovarian tumorigenesis , 2007, International Journal of Gynecologic Cancer.

[27]  Yusuke Nakamura,et al.  Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. , 2007, Cancer research.

[28]  N. Natarajan,et al.  Ovarian cancer incidence in the United States, 1992-1999. , 2005, Gynecologic oncology.

[29]  P. Carlsson,et al.  Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β , 2003, British Journal of Cancer.

[30]  M. Gore,et al.  Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. , 2002, The Lancet. Oncology.

[31]  A. Whittemore,et al.  Survival among U.S. women with invasive epithelial ovarian cancer. , 2002, Gynecologic oncology.

[32]  Yue Xiong,et al.  p15PAF, a novel PCNA associated factor with increased expression in tumor tissues , 2001, Oncogene.

[33]  J. Palacios,et al.  β-Catenin Expression Pattern in Stage I and II Ovarian Carcinomas : Relationship with β-Catenin Gene Mutations, Clinicopathological Features, and Clinical Outcome , 1999 .

[34]  Tatsuya Kato,et al.  Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. , 2012, Lung cancer.

[35]  H. Osada,et al.  MicroRNAs in biological processes and carcinogenesis. , 2007, Carcinogenesis.